[go: up one dir, main page]

WO2012165610A1 - Composition pour maintenir ou améliorer une fonction de barrière cutanée - Google Patents

Composition pour maintenir ou améliorer une fonction de barrière cutanée Download PDF

Info

Publication number
WO2012165610A1
WO2012165610A1 PCT/JP2012/064259 JP2012064259W WO2012165610A1 WO 2012165610 A1 WO2012165610 A1 WO 2012165610A1 JP 2012064259 W JP2012064259 W JP 2012064259W WO 2012165610 A1 WO2012165610 A1 WO 2012165610A1
Authority
WO
WIPO (PCT)
Prior art keywords
barrier function
taurine
skin barrier
skin
aging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2012/064259
Other languages
English (en)
Japanese (ja)
Inventor
憲一 高野
拓人 武井
友紀 井野口
周子 武藤
知佳 真邉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority to JP2013518184A priority Critical patent/JP6238406B2/ja
Publication of WO2012165610A1 publication Critical patent/WO2012165610A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to an oral composition having an action of maintaining a skin barrier function in normal skin and restoring the skin barrier function in broken skin. More specifically, taurine is used as an active ingredient, mainly suppressing the decrease in skin barrier function due to aging, restoring the reduced skin barrier function to a normal level, and functioning when the skin barrier function is destroyed. It is related with the composition for oral use which has the effect
  • Such a skin state is sometimes referred to as “a state in which the skin barrier function is lowered”.
  • the skin barrier function refers to the ability of the stratum corneum to retain moisture. If this decreases, the skin surface tends to dry out, causing problems such as various bacteria, allergens, and irritating factors. Sometimes.
  • This skin barrier function is evaluated using the skin stratum corneum water content and transepidermal water transpiration (TEWL) as an index (see Non-Patent Document 1), but atopy is a typical disease that causes abnormal skin barrier function. In patients with atopic dermatitis, there is a report that the stratum corneum moisture content is about one-fifth and the transdermal moisture transpiration amount is about four times that of healthy individuals (see Non-Patent Document 2).
  • Non-Patent Document 3 In order to evaluate the state of wrinkles, there are known models that induce wrinkles by continuously irradiating mice with ultraviolet rays, and models that induce wrinkles by feeding mice with special diets that are deficient in minerals and fatty acids (non-wrinkle). (See Patent Documents 4 and 5).
  • NMF Natural Moisturizing Factor
  • Taurine (2-aminoethanesulfonic acid) is a sulfur-containing amino acid with a simple chemical structure with a molecular weight of 125.15. Unlike amino acids that make up proteins, it acts like vitamins and hormones, as well as cranial nerves. It is known to exhibit various pharmacological actions including system, circulatory system, and hepatobiliary system (see Non-Patent Document 6). As described above, taurine has been attracting attention as a physiologically active substance and has been widely used. However, there is no report that it is incorporated into an oral composition and provided as an agent for maintaining or improving the skin barrier function.
  • Non-Patent Document 7 it is known that wrinkles occur when the elasticity of the skin tissue decreases due to natural aging due to aging and photoaging due to ultraviolet rays or the like.
  • the present invention has an action of preventing or improving wrinkles caused by aging while suppressing a decrease in skin barrier function caused by aging, or promoting repair of skin barrier function destroyed due to aging.
  • An object of the present invention is to provide a new type of oral composition.
  • the inventors of the present invention have found that the amount of taurine in the skin decreases with aging through examination of how factors involved in skin components change due to aging.
  • taurine was orally administered to mice with reduced skin barrier function, and the skin barrier function of the mouse was evaluated by measuring the skin stratum corneum water content and transepidermal water transpiration (TEWL).
  • TEWL transepidermal water transpiration
  • the inventors have found that it has the action of suppressing the generation of wrinkles due to aging or improving the generated wrinkles.
  • an oral composition that has an action of preventing or improving wrinkles caused by aging while suppressing a decrease in skin barrier function due to aging or promoting repair of a broken skin barrier function. It became possible to provide.
  • the present invention relates to an oral composition for maintaining or improving the skin barrier function, characterized by containing taurine as an active ingredient.
  • skin barrier function means the ability of the stratum corneum of skin to retain moisture. The state of skin barrier function is judged using keratin water content and transepidermal water transpiration as indicators, and when the skin barrier function decreases, keratin water content decreases and transepidermal water transpiration increases, while skin barrier function When improved, the amount of stratum corneum increases and the amount of transepidermal water transpiration decreases.
  • the oral composition of the present invention is particularly effective for suppressing or improving a decrease in skin barrier function due to aging.
  • aging as used herein includes natural aging caused by aging and photoaging caused by ultraviolet rays and the like, but the oral composition of the present invention can be applied to any reduction in skin barrier function due to aging. is there.
  • the oral composition of the present invention is effective in preventing and improving skin wrinkles, particularly wrinkles caused by aging.
  • the oral composition of the present invention can be in the form of a pharmaceutical composition or a food or drink. Since the oral composition of the present invention has an action of maintaining or improving the skin barrier function, it is administered orally for the prevention or improvement (treatment) of symptoms and diseases caused by the reduction of the skin barrier function, such as wrinkles. It can be suitably used as a pharmaceutical composition to be used or as a food or drink that is taken daily for maintaining or improving the skin barrier function.
  • the oral composition of the present invention can be provided by a conventional method, for example, as a solid preparation for internal use such as a powder, granule, tablet, or a liquid preparation such as a drink.
  • a pharmaceutical carrier suitable for each form is used, but there is no particular limitation as long as it is suitable for oral administration.
  • the oral composition of the present invention When used as a pharmaceutical composition, one or more other components effective for maintaining or improving the skin barrier function can be blended. Moreover, you may use together with the other pharmaceutical composition effective in maintenance or improvement of a skin barrier function.
  • the oral composition of the present invention when used as a food or drink, can be, for example, a health food, a functional food, a food for specified health use, a nutritional supplement, a food for the sick, or a food additive. .
  • food and drink include liquid products such as drinks, soups, milk drinks, soft drinks, tea drinks, alcoholic drinks, jelly-like drinks, functional drinks; oils such as edible oils, dressings, mayonnaise, margarines Products containing carbohydrates; Foods containing carbohydrates such as rice, noodles and bread; Livestock processed foods such as ham and sausage; Fish processed foods such as kamaboko, dried fish and salted; Vegetable processed foods such as pickles; Semis such as jelly and yogurt Solid foods; Fermented foods such as miso and fermented beverages; Various confectionery such as Western confectionery, Japanese confectionery, candy, gums, gummi, frozen confectionery, ice confectionery; Retort products such as curry, sauce, Chinese soup; Examples include instant foods such as instant miso soup and foods for microwave ovens. Furthermore, health foods and drinks prepared in the form of powder, granules, tablets, capsules, liquid, paste or jelly are also included.
  • Manufacture of food and drink can be carried out by manufacturing techniques known in the technical field.
  • the preferred form of the oral composition of the present invention is an aqueous beverage (for example, an internal liquid such as a drink or a liquid product such as a drink).
  • An aqueous beverage in a container such as a bottle having a pH adjusted to 2.5 to 7.0, preferably 4.5 to 6.5.
  • An appropriate pH adjuster can be used for adjusting the pH in consideration of the ingestibility and the like. Examples of such pH adjusters include citric acid, malic acid, fumaric acid, adipic acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, phosphoric acid, or salts thereof.
  • Water-based beverages prepared in this way are provided by filling them into molded containers (so-called PET bottles) based on polyethylene terephthalate, metal cans, paper containers combined with metal foil and plastic films, glass bottles, etc. Is done.
  • the content (formulation) of “taurine” is 0.1 to 10% by mass in the oral composition, preferably 0.5 to 5% by mass, more preferably 1 to 3% by mass. If it is 0.1% by mass or less, it is not preferable from the viewpoint of maintaining and improving the skin barrier function, and if it exceeds 10% by mass, it is not preferable from the viewpoint of solubility of taurine when it is in the form of a beverage.
  • the present invention also provides a method for maintaining or improving the skin barrier function in a subject, characterized by administering or ingesting the oral composition of the present invention to the subject. Moreover, the method for suppressing or improving the fall of the skin barrier function by the aging in a subject characterized by administering the composition for oral administration of this invention to a subject is also provided. Furthermore, the present invention also provides a method for preventing or improving wrinkles due to aging in a subject, which comprises administering the oral composition of the present invention to the subject.
  • the product of the oral composition of the present invention may be labeled with an indication that it is used to maintain or improve the skin barrier function.
  • labeled product or instructions means that the product body, container, packaging, etc. are marked, or instructions, package inserts, promotional materials, or other printed materials that disclose product information. It means that the display is attached to.
  • the indication to be used to maintain or improve the skin barrier function may include information on the mechanism by which the skin barrier function is maintained or improved by administering or ingesting the oral composition of the present invention. it can. Moreover, the information regarding the symptom resulting from the fall of a skin barrier function, or being used for the prevention or improvement of a disease can be included.
  • Test Example 2 Change of Taurine Content in the Skin by Oral Administration of Taurine Using 5-week-old HR-1 female mice (purchased from Japan SLC Co., Ltd.), 10 mice per group, reared up to 32 weeks of age, A 3% aqueous solution of taurine was administered for 4 weeks. On the other hand, purified water was administered to the control group. After administration, skin was collected in the same manner as in Test Example 1, and the amount of taurine in the skin was measured.
  • Test Example 3 Effect of Taurine Administration on Skin Function Decreased by Ultraviolet Irradiation Using 7-week-old HR-1 male mice (purchased from Japan SLC Co., Ltd.), 10 mice per group, and ultraviolet rays (irradiation on the back of the mice) A dose of 70-100 mJ / cm 2 ) was irradiated 3 times a week for 4 weeks. Meanwhile, 3% aqueous taurine solution was administered as a mixed water. On the other hand, purified water was administered to the control group. After the final administration, the horny layer moisture content and transdermal moisture transpiration of the back skin were measured.
  • Test Example 4 Effect of Taurine Administration Before Wrinkle Generation on Wrinkles Generated by Ultraviolet Irradiation Using 8 week old HR-1 male mice (purchased from Japan SLC Co., Ltd.), 9 to 10 animals per group The back of the mouse was irradiated with ultraviolet rays (irradiation amount 70-100 mJ / cm 2 ) three times a week for 8 weeks. Meanwhile, 3% aqueous taurine solution was administered as a mixed water. On the other hand, purified water was administered to the control group. After the final administration, wrinkles on the back skin were evaluated according to the above criteria and scored.
  • Test Example 5 Effect of Taurine Administration on Wrinkles Generated by Ultraviolet Irradiation Using 7-week-old HR-1 male mice (purchased from Japan SLC Co., Ltd.), 10 mice per group, and ultraviolet rays (irradiation dose on the back of mice) (70-100 mJ / cm 2 ) was irradiated 3 times a week for 12 weeks. From 8 weeks after the start of ultraviolet irradiation (after the occurrence of significant wrinkles was confirmed), a 3% taurine aqueous solution was administered as a mixed water for 4 weeks. On the other hand, purified water was administered to the control group. After the final administration, wrinkles on the back skin were evaluated according to the above criteria and scored.
  • an oral composition having an action of suppressing deterioration of skin barrier function or promoting repair of destroyed skin barrier function and preventing or improving wrinkles caused by aging is used, for example. It is expected to contribute to the development of the anti-aging industry and the like by providing it in the form of an aqueous beverage such as liquids and drinks.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition orale pour maintenir ou améliorer une fonction de barrière cutanée, caractérisée en ce qu'elle contient de la taurine en tant que principe actif ; ou sur une composition orale pour prévenir ou améliorer le plissement lié à l'âge, caractérisée en ce qu'elle contient de la taurine en tant que principe actif.
PCT/JP2012/064259 2011-06-03 2012-06-01 Composition pour maintenir ou améliorer une fonction de barrière cutanée Ceased WO2012165610A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013518184A JP6238406B2 (ja) 2011-06-03 2012-06-01 皮膚バリア機能の維持又は改善のための組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2011124927 2011-06-03
JP2011-124927 2011-06-03
JP2012088128 2012-04-09
JP2012-088128 2012-04-09

Publications (1)

Publication Number Publication Date
WO2012165610A1 true WO2012165610A1 (fr) 2012-12-06

Family

ID=47259461

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/064259 Ceased WO2012165610A1 (fr) 2011-06-03 2012-06-01 Composition pour maintenir ou améliorer une fonction de barrière cutanée

Country Status (3)

Country Link
JP (2) JP6238406B2 (fr)
TW (1) TW201311289A (fr)
WO (1) WO2012165610A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4186498A1 (fr) * 2021-11-29 2023-05-31 Amorepacific Corporation Promoteur de production/activation de reeline/vegf-c et composition externe pour la peau et leur utilisation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7131785B1 (ja) * 2021-08-03 2022-09-06 宇航人ジャパン株式会社 皮膚保湿剤および皮膚バリア機能改善剤

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05310548A (ja) * 1992-05-13 1993-11-22 Taisho Pharmaceut Co Ltd 皮膚外用剤
JPH05310549A (ja) * 1992-05-13 1993-11-22 Taisho Pharmaceut Co Ltd 皮膚外用剤
JP2005514342A (ja) * 2001-11-01 2005-05-19 ニュー テクノロジー リサーチ リミテッド 栄養補助作用および栄養強化作用を有する薬用−食調製物
JP2007514695A (ja) * 2003-12-18 2007-06-07 ネステク ソシエテ アノニム フラバノン類を含んでいる皮膚、毛髪及び外皮の健康を改善するための組成物
JP2008024623A (ja) * 2006-07-20 2008-02-07 Taisho Pharmaceut Co Ltd 経口用組成物
JP2008063321A (ja) * 2006-08-10 2008-03-21 Kao Corp 筋肉老化抑制剤
JP2010538674A (ja) * 2007-09-19 2010-12-16 オフサルモファーマ・アクチェンゲゼルシャフト 栄養補助剤およびそのような補助剤を含む強化食品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3403780B2 (ja) * 1993-11-08 2003-05-06 相互薬工株式会社 化粧料
GB0113348D0 (en) * 2001-06-01 2001-07-25 Mars Uk Ltd Skin diet
JP4470212B2 (ja) * 2006-11-11 2010-06-02 ビーエイチエヌ株式会社 皮膚改善剤
JP2010202520A (ja) * 2009-02-27 2010-09-16 Kaneka Corp 皮膚改善剤及び美容健康用経口組成物
WO2011007885A1 (fr) * 2009-07-16 2011-01-20 サンスター株式会社 Matière à teneur en protéoglycane

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05310548A (ja) * 1992-05-13 1993-11-22 Taisho Pharmaceut Co Ltd 皮膚外用剤
JPH05310549A (ja) * 1992-05-13 1993-11-22 Taisho Pharmaceut Co Ltd 皮膚外用剤
JP2005514342A (ja) * 2001-11-01 2005-05-19 ニュー テクノロジー リサーチ リミテッド 栄養補助作用および栄養強化作用を有する薬用−食調製物
JP2007514695A (ja) * 2003-12-18 2007-06-07 ネステク ソシエテ アノニム フラバノン類を含んでいる皮膚、毛髪及び外皮の健康を改善するための組成物
JP2008024623A (ja) * 2006-07-20 2008-02-07 Taisho Pharmaceut Co Ltd 経口用組成物
JP2008063321A (ja) * 2006-08-10 2008-03-21 Kao Corp 筋肉老化抑制剤
JP2010538674A (ja) * 2007-09-19 2010-12-16 オフサルモファーマ・アクチェンゲゼルシャフト 栄養補助剤およびそのような補助剤を含む強化食品

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FUJII, M. ET AL.: "Atopic dermatitis-like pruritic skin inflammation caused by feeding a special diet to HR-1 hairless mice", EXPERIMENTAL DERMATOLOGY, vol. 14, no. 6, 2005, pages 460 - 468 *
HACHIRO TAGAMI ET AL.: "Studies on the barrier function and water-holding capacity of the stratum corneum", FRAGRANCE JOURNAL, vol. 32, no. 9, 2004, pages 10 - 16 *
HIDEO SATSU: "Taurine no Tasai na Seiri Sayo to Kino", KAGAKU TO SEIBUTSU, vol. 45, no. 4, 2007, pages 273 - 281 *
IZUMI HORII: "Mechanism of Skin Wrinkling and Anti-Wrinkle Agents", JOURNAL OF JAPANESE COSMETIC SCIENCE SOCIETY, vol. 25, no. 2, 2001, pages 91 - 95 *
MASAMITSU ICHIHASHI: "Hifu no Roka to Shiwa no Keisei", FRAGRANCE JOURNAL, vol. 32, no. 5, 2004, pages 24 - 30 *
SHIGERU MORIWAKI: "Effectiveness of fibroblast elastase inhibitors for anti-wrinkling", FRAGRANCE JOURNAL, vol. 32, no. 5, May 2004 (2004-05-01), pages 46 - 51 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4186498A1 (fr) * 2021-11-29 2023-05-31 Amorepacific Corporation Promoteur de production/activation de reeline/vegf-c et composition externe pour la peau et leur utilisation
US11992471B2 (en) 2021-11-29 2024-05-28 Amorepacific Corporation Reelin/VEGF-C production/activation promoter and skin external composition using the same

Also Published As

Publication number Publication date
JP2017025097A (ja) 2017-02-02
TW201311289A (zh) 2013-03-16
JP6238406B2 (ja) 2017-11-29
JP6222503B2 (ja) 2017-11-01
JPWO2012165610A1 (ja) 2015-02-23

Similar Documents

Publication Publication Date Title
CN105792837B (zh) 包含胶原蛋白肽、弹性蛋白肽及蛋白多糖的组合物
JP6244594B2 (ja) 老化抑制剤
JP3495712B2 (ja) 食品組成物
JP6374579B2 (ja) 環状ジペプチドを有効成分とする皮膚保湿機能改善剤
JP2014508139A (ja) フラボン系化合物の新規な用途
WO2010096564A2 (fr) Compléments alimentaires contenant des acides gras oméga-3 polyinsaturés et des bactéries probiotiques avec bénéfices gastro-intestinaux et dermatologiques potentiels
JP4255432B2 (ja) 異常蛋白質除去用組成物
JP2010202520A (ja) 皮膚改善剤及び美容健康用経口組成物
JP5712393B2 (ja) コラーゲン類吸収促進剤及びその利用
JP2002003393A (ja) 線維芽細胞増殖作用剤、美容用飲食品および皮膚化粧料
EP3115047A1 (fr) Agent prévenant la débilité
JP6222503B2 (ja) 皮膚バリア機能の維持又は改善のための組成物
CN110381965A (zh) 用于促进体内bdnf量增加的组合物
JP6482930B2 (ja) 皮膚化粧料および飲食品
JP6858986B2 (ja) 美容組成物
JP2008308505A (ja) 異常蛋白質除去用組成物
JP2005015364A (ja) 抗酸化組成物、皮膚老化防止用組成物、抗炎症組成物及び脂質代謝改善用組成物
TWI566772B (zh) 美白劑及黑色素生成抑制劑
CN109803646A (zh) 酮体生成促进用组合物
JP4672304B2 (ja) 脂肪分解促進剤
JP7270996B2 (ja) 美容組成物
JP2019064929A (ja) 液体組成物、その白濁改善剤、臭気改善剤、及び製造方法
JP2018201345A (ja) 肝臓加水分解物とドクダミエキスを含む組成物
JP2017007966A (ja) 美容組成物
RU151963U1 (ru) Диетическая биодобавка "раполан-с"

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12793421

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2013518184

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12793421

Country of ref document: EP

Kind code of ref document: A1